Ethanol blocks long-term potentiation of GABAergic synapses in the ventral tegmental area involving mu-opioid receptors.
It is well documented that ethanol exposure alters GABA (gamma-aminobutyric acid)-releasing synapses, and ethanol addiction is associated with endogenous opioid system. Emerging evidence indicates that opioids block long-term potentiation in the fast inhibitory GABA(A) receptor synapses (LTP(GABA)) onto dopamine-containing neurons in the ventral tegmental area (VTA), a brain region essential for reward-seeking behavior. However, how ethanol affects LTP(GABA) is not known. We report here that in acute midbrain slices from rats, clinically relevant concentrations of ethanol applied both in vitro and in vivo prevents LTP(GABA), which is reversed, respectively, by in vitro and in vivo administration of naloxone, a mu-opioid receptor (MOR) antagonist. Furthermore, the blockade of LTP(GABA) induced by a brief in vitro ethanol treatment is mimicked by DAMGO ([D-Ala(2), N-MePhe(4), Gly-ol]-enkephalin), a MOR agonist. Paired-pulse ratios are similar in slices, 24 h after in vivo injection with either saline or ethanol. Sp-cAMPS, a stable cAMP analog, and pCPT-cGMP, a cGMP analog, potentiates GABA(A)-mediated inhibitory postsynaptic currents in slices from ethanol-treated rats, indicating that a single in vivo ethanol exposure does not maximally increase GABA release, instead, ethanol produces a long-lasting inability to generate LTP(GABA). These neuroadaptations to ethanol might contribute to early stage of addiction.
Guan
Yan-zhong
YZ
Department of Anesthesiology, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, NJ 07103, USA.
Ye
Jiang-Hong
JH
D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D002492:Central Nervous System Depressants / Q000494:pharmacology*; D000242:Cyclic AMP / Q000031:analogs & derivatives / Q000494:pharmacology; D006152:Cyclic GMP / Q000031:analogs & derivatives / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D004558:Electric Stimulation / Q000379:methods; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D000431:Ethanol / Q000494:pharmacology*; D066298:In Vitro Techniques; D053444:Inhibitory Postsynaptic Potentials / Q000187:drug effects; D017774:Long-Term Potentiation / Q000187:drug effects*; D009474:Neurons / Q000166:cytology / Q000187:drug effects*; D018408:Patch-Clamp Techniques; D051381:Rats; D017207:Rats, Sprague-Dawley; D017450:Receptors, Opioid, mu / Q000187:drug effects / Q000378:metabolism*; D013569:Synapses / Q000187:drug effects* / Q000378:metabolism; D013873:Thionucleotides / Q000494:pharmacology; D013997:Time Factors; D017557:Ventral Tegmental Area / Q000166:cytology*; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
D000701:Analgesics, Opioid; C474799:CPT-cGMP; D002492:Central Nervous System Depressants; D004791:Enzyme Inhibitors; D017450:Receptors, Opioid, mu; D013873:Thionucleotides; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; C016957:adenosine-3',5'-cyclic phosphorothioate; D000431:Ethanol; D005680:gamma-Aminobutyric Acid; D000242:Cyclic AMP; D006152:Cyclic GMP; D004298:Dopamine
J Neurosci. 1997 Jan 15;17(2):796-803
8987801
Neuroscience. 2008 Apr 22;153(1):240-8
18343590
Annu Rev Neurosci. 2006;29:565-98
16776597
Neuropsychopharmacology. 2009 Jun;34(7):1829-42
19194373
Alcohol. 2000 Oct;22(2):85-90
11113622
Physiol Behav. 2004 Apr;81(2):339-58
15159175
Neuropsychopharmacology. 2009 Apr;34(5):1233-44
18784647
Synapse. 2001 Sep 15;41(4):311-28
11494402
Alcohol Clin Exp Res. 2008 Jun;32(6):1040-8
18422836
Eur J Neurosci. 2009 Jul;30(2):272-8
19614973
Neuroscience. 2004;127(3):777-84
15283974
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2938-42
16477003
Neuropsychopharmacology. 2009 Jan;34(2):307-18
18596684
Alcohol. 2003 Apr;29(3):165-71
12798972
J Neurosci. 2004 Oct 13;24(41):8961-74
15483115
J Neurosci. 1998 Oct 1;18(19):8003-15
9742167
Pharmacol Ther. 2005 Jul;107(1):80-98
15963352
Pharmacol Ther. 2006 Sep;111(3):533-54
16427127
Proc Natl Acad Sci U S A. 1986 Jun;83(11):4071-5
2424017
J Neurosci. 2002 Mar 15;22(6):2074-82
11896147
Psychopharmacology (Berl). 2008 Dec;201(2):261-71
18688603
J Neurosci. 2008 Nov 26;28(48):12672-81
19036960
Pharmacol Biochem Behav. 1998 Mar;59(3):627-35
9512064
Neuron. 2008 Jul 31;59(2):288-97
18667156
J Physiol. 2007 May 1;580(Pt.3):731-43
17303643
J Neurosci. 2001 Dec 1;21(23):RC184
11717387
Nature. 2007 Apr 26;446(7139):1086-90
17460674
Curr Drug Abuse Rev. 2008 Jun;1(2):239-52
19630722
J Neurosci Methods. 2006 Dec 15;158(2):251-9
16842860
Trends Pharmacol Sci. 1992 May;13(5):185-93
1604711
Annu Rev Physiol. 2002;64:355-405
11826273
J Pharmacol Exp Ther. 1999 Dec;291(3):1045-53
10565823
Nat Rev Neurosci. 2001 Oct;2(10):695-703
11584307
Psychopharmacology (Berl). 1997 Jan;129(2):99-111
9040115
Alcohol Clin Exp Res. 2007 Jul;31(7):1106-13
17577392
J Neurosci. 2003 Nov 5;23(31):9981-6
14602811
Alcohol Clin Exp Res. 2001 Jan;25(1):25-33
11198711
Trends Neurosci. 1995 Jan;18(1):22-9
7535487
Synapse. 2001 Sep 1;41(3):221-9
11418935
Synapse. 1993 Jan;13(1):63-73
8427014
Alcohol Clin Exp Res. 2009 Jun;33(6):1033-43
19302084
J Physiol. 2008 Mar 15;586(6):1487-93
18079157
J Pharmacol Exp Ther. 2009 May;329(2):625-33
19225162
J Physiol. 1992 May;450:455-68
1331427
Neurochem Int. 1999 Aug;35(2):115-23
10405995
Nat Rev Neurosci. 2007 Nov;8(11):844-58
17948030
Neurosci Res. 2003 Oct;47(2):153-60
14512140
J Neurosci. 1992 Feb;12(2):483-8
1346804
Neuropharmacology. 2002 Jun;42(8):1065-78
12128008
J Pharmacol Exp Ther. 2004 Oct;311(1):282-9
15169831